$MCLE
Medicale Corp.

2022 Q3 Form 10-K Financial Statement

#000168316822008165 Filed on December 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.35K $46.42K $32.15K
YoY Change 119.08% 44.39% 1574.48%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $600.00 $2.400K $2.400K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $14.35K $46.42K $32.15K
YoY Change 119.08% 44.38% 1574.48%
Operating Profit -$46.42K -$32.15K
YoY Change 44.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.35K -$46.42K -$32.15K
YoY Change 119.08% 44.38% 1574.48%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.35K -$46.42K -$32.15K
YoY Change 119.08% 44.38% 1574.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share $0.00 -$0.01 -$9.456K
COMMON SHARES
Basic Shares Outstanding 5.920M shares 5.920M shares 3.616M shares
Diluted Shares Outstanding 5.920M shares 3.616M shares

Balance Sheet

Concept 2022 Q3 2022 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $18.48K
YoY Change -100.0% -100.0%
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $0.00 $0.00 $18.68K
YoY Change -100.0% -100.0% 9240.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $0.00
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $9.600K
YoY Change -100.0% -100.0% -20.0%
TOTAL ASSETS
Total Short-Term Assets $0.00 $0.00 $18.68K
Total Long-Term Assets $0.00 $0.00 $9.600K
Total Assets $0.00 $0.00 $28.28K
YoY Change -100.0% -100.0% 131.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.00K $37.00K $25.00K
YoY Change 48.0% 48.0% 92.31%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.77K $54.77K $36.63K
YoY Change 49.53% 49.52% 169.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $54.77K $54.77K $36.63K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $54.77K $54.77K $36.63K
YoY Change 49.52% 49.52% 169.34%
SHAREHOLDERS EQUITY
Retained Earnings -$80.49K
YoY Change 136.23%
Common Stock $592.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$54.77K -$54.77K -$8.360K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $0.00 $28.28K
YoY Change -100.0% -100.0% 131.8%

Cashflow Statement

Concept 2022 Q3 2022 2021
OPERATING ACTIVITIES
Net Income -$14.35K -$46.42K -$32.15K
YoY Change 119.08% 44.38% 1574.48%
Depreciation, Depletion And Amortization $600.00 $2.400K $2.400K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$3.550K -$24.62K -$17.75K
YoY Change 20.75% 38.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $25.20K
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.550K $6.144K 36.23K
YoY Change 446.15% -83.04% 6867.31%
NET CHANGE
Cash From Operating Activities -3.550K -$24.62K -17.75K
Cash From Investing Activities 0.000 $0.00 0.000
Cash From Financing Activities 3.550K $6.144K 36.23K
Net Change In Cash -0.000000000001819 -$18.48K 18.48K
YoY Change -100.0% -199.97% 3453.85%
FREE CASH FLOW
Cash From Operating Activities -$3.550K -$24.62K -$17.75K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
200 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
0 usd
CY2021Q3 us-gaap Assets Current
AssetsCurrent
18675 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9600 usd
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
0114
CY2022 dei City Area Code
CityAreaCode
702
CY2022 dei Local Phone Number
LocalPhoneNumber
6054432
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001827855
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2021Q3 MCLE Accumulated Impairment
AccumulatedImpairment
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
333-250025
CY2022 dei Entity Registrant Name
EntityRegistrantName
MEDICALE CORP.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1556944
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
Otar Lortkifanidze 16
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Tbilisi
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Public Float
EntityPublicFloat
0 usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5920000 shares
CY2022 dei Auditor Firm
AuditorFirmId
6258
CY2022 dei Auditor Name
AuditorName
Mac Accounting Group, LLP
CY2022 dei Auditor Location
AuditorLocation
Midvale, Utah
CY2022Q3 us-gaap Cash
Cash
0 usd
CY2021Q3 us-gaap Cash
Cash
18475 usd
CY2022Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 usd
CY2022Q3 us-gaap Assets
Assets
0 usd
CY2021Q3 us-gaap Assets
Assets
28275 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
17774 usd
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11630 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
37000 usd
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
25000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
54774 usd
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36630 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25128 usd
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25128 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80494 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34075 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-54774 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-8355 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 usd
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28275 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2021 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46419 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32152 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
46419 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
32152 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-46419 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-32152 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46419 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32152 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46419 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-32152 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3615616 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3615616 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1403 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25200 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-32152 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-8355 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46419 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-54774 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46419 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-32152 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400 usd
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400 usd
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7200 usd
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12000 usd
CY2022 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
-200 usd
CY2021 us-gaap Increase Decrease In Notes Receivable Related Parties
IncreaseDecreaseInNotesReceivableRelatedParties
-0 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24619 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17752 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25200 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
6144 usd
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
11027 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6144 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36227 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18475 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
18475 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18475 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18475 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80494 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zczFfkEfW7m" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zGZxnzdYp2D1">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7200 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_z7DnBwkrJrll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zzcKVITh4bYe">Risks and Uncertainties</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2022Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
12000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12000 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4800 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2400 usd
CY2022Q3 MCLE Accumulated Impairment
AccumulatedImpairment
7200 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9600 usd
CY2022Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
80494 usd
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21 pure
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11700 usd
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5200 usd
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5200 usd
CY2021Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3400 usd
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16900 usd
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8600 usd
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd

Files In Submission

Name View Source Status
0001683168-22-008165-index-headers.html Edgar Link pending
0001683168-22-008165-index.html Edgar Link pending
0001683168-22-008165.txt Edgar Link pending
0001683168-22-008165-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mcle-20220930.xsd Edgar Link pending
medicale_ex3101.htm Edgar Link pending
medicale_ex3201.htm Edgar Link pending
medicale_i10k-093022.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
mcle-20220930_cal.xml Edgar Link unprocessable
mcle-20220930_pre.xml Edgar Link unprocessable
mcle-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
medicale_i10k-093022_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mcle-20220930_def.xml Edgar Link unprocessable